Temodar and Ms contin drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Temodar (temozolomide) and Ms contin (morphine sulfate). Common drug interactions include injury among females and haematocrit decreased among males.

The phase IV clinical study analyzes what interactions people have when they take Temodar and Ms contin. It is created by eHealthMe based on reports of 19 people who take the same drugs from the FDA, and is updated regularly.

What is Temodar?

Temodar has active ingredients of temozolomide. It is often used in glioblastoma multiforme. eHealthMe is studying from 6,683 Temodar users. Check the latest studies of Temodar.

What is Ms contin?

Ms contin has active ingredients of morphine sulfate. It is often used in pain. eHealthMe is studying from 69,289 Ms contin users. Check the latest studies of Ms contin.

On Jul, 18, 2026

19 people who take Temodar and Ms contin together, and have interactions are studied.

Temodar and Ms contin drug interactions.

What are the common drug interactions of Temodar and Ms Contin, by gender? *:

female:

Injury
Insomnia (sleeplessness)
Intervertebral disc degeneration (spinal disc degeneration)
Kidney small
Mental status changes (general changes in brain function, such as confusion, amnesia (memory loss), loss of alertness, loss of orientation)
Multiple fractures
Neuropathic ulcer (nerve damage in foot leads to sensation loss and person puts lots of pressure and gets ulcer)
Oedema peripheral (superficial swelling)
Osteoarthritis (a joint disease caused by cartilage loss in a joint)
Osteolysis (dissolution of bone)

male:

Haematocrit decreased
Blood potassium decreased
Arteriosclerosis (thickening and hardening of arteries)
Ascites (accumulation of fluid in the abdominal cavity)
Atelectasis (partial or complete collapse of the lung)
Bladder hypertrophy (bladder overgrowth- increase in cell size)
Bladder obstruction
Blood albumin decreased
Blood alkaline phosphatase increased
Blood chloride increased

What are the common drug interactions of Temodar and Ms Contin, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

Chest pain
Pulmonary embolism (blockage of the main artery of the lung)

20-29:

n/a

30-39:

n/a

40-49:

Disease progression
Ecchymosis (a discoloration of the skin resulting from bleeding underneath)
Fall
Haematocrit decreased
Thrombocytopenia (decrease of platelets in blood)
White blood cell count increased
Blood alkaline phosphatase increased
Blood lactate dehydrogenase increased

50-59:

Agranulocytosis (a deficiency of granulocytes in the blood, causing increased vulnerability to infection)
Aplastic anaemia (blood disorder in which the body's bone marrow doesn't make enough new blood cells)
Asthenia (weakness)
Disease progression
Leukopenia (less number of white blood cells in blood)
Overdose
Pyrexia (fever)
Thrombocytopenia (decrease of platelets in blood)
Uterine leiomyosarcoma (uterus cancer of smooth muscle connective tissue)

60+:

Blood lactate dehydrogenase increased
Diabetes mellitus (diabetes, caused by a deficiency of the pancreatic hormone insulin)
Bone fissure
Bronchitis (inflammation of the mucous membrane in the bronchial tubes)
Bruxism (habitual grinding of the teeth, typically during sleep)
Cellulitis (infection under the skin)
Cerebral infarction (less blood supply to brain resulting tissue damage)
Confusional state
Culture urine positive
Decubitus ulcer (a chronic ulcer of the skin caused by prolonged pressure on it)

What are the existing conditions these people have? *

High Blood Pressure: 2 people, 10.53%
Uterine Leiomyosarcoma (uterus cancer of smooth muscle connective tissue): 1 person, 5.26%
Pulmonary Tuberculosis (lungs tuberculosis): 1 person, 5.26%
Pulmonary Embolism (blockage of the main artery of the lung): 1 person, 5.26%
Neuroendocrine Tumor: 1 person, 5.26%
Metastatic Malignant Melanoma (spreadable cancer tumour of melanine): 1 person, 5.26%
Histiocytosis Haematophagic: 1 person, 5.26%
Glioblastoma (most common and most aggressive malignant primary brain tumour in humans): 1 person, 5.26%
Ewing's Sarcoma (malignant small, round, blue cell tumour): 1 person, 5.26%
Breakthrough Pain: 1 person, 5.26%

* Approximation only. Some reports may have incomplete information.

Do you take Temodar and Ms contin?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously